Mednet Logo
HomeRadiation OncologyQuestion

Would you hold cabozantinib for radiation therapy, or is concurrent use safe?

2
1 Answers
Mednet Member
Mednet Member
Radiation Oncology · University of Washington School of Medicine

Cabozantinib is a VEGFR-TKI which potentially carries a risk of hemorrhage and bowel perforation when given together with high dose RT or SBRT though, tangible data are lacking. We will typically hold the drug for 3 days before starting SBRT and will resume 3 days after SBRT (not evidence-based).

Register or Sign In to see full answer